The left is up in arms over the pharmaceutical CEO who raised prices for a drug mostly used by AIDS patients by more than 5,000 percent, but experts CNBC interviewed said regulatory barriers helped make it possible.
Founder and CEO of Turing Pharmaceutical, Martin Shkreli bought the generic drug Daraprim, which is used for parasitic infections in pregnant women and immunocompromised individuals. He hiked its cost from $13.50 a pill to $750, a whopping 5,455 percent.


